Hepatitis B Vaccine (Recombinant) is a solution of Hepatitis B surface antigen used to immunize patients against Hepatitis B. Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix.
- Mechanism
- Curator reviewed
ENGERIX®-B induces specific humoral antibodies against HBsAg (anti-HBs antibodies). It is generally accepted that an anti-HBs titre greater than 10 IU/L correlates with protection against hepatitis B virus infection. More than 90% of healthy adults, children and neonates developed protective anti-HBs titres one month after completing a primary vaccination schedule of ENGERIX®-B (hepatitis B vaccine (recombinant)).
- Primary indication
- Active immunization against hepatitis B virus infection.Curator reviewed · 2 structured indications
- First approval
- Canada, 2001 · United States, 1986 · European Union, 2016
- Also known as
- HBSAG · Hepatitis B antigen · Hepatitis B surface antigen · Hepatitis B Surface Antigen (rDNA) · Hepatitis B surface antigen (recombinant)
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which other approved drugs treat the same conditions as Hepatitis B Vaccine (Recombinant), and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account